Powder: -20°C for 3 years | In solvent: -80°C for 1 year
AN-019 (NRC-019) is a Bcr-Abl kinase inhibitor with antitumor activity for the study of chronic myelogenous leukemia (CML) and breast cancer.
パッケージサイズ | 在庫状況 | 単価(税別) |
---|---|---|
1 mg | 在庫あり | ¥ 67,500 |
5 mg | 在庫あり | ¥ 166,000 |
10 mg | 在庫あり | ¥ 226,500 |
25 mg | 在庫あり | ¥ 349,000 |
50 mg | 在庫あり | ¥ 454,500 |
100 mg | 在庫あり | ¥ 574,000 |
説明 | AN-019 (NRC-019) is a Bcr-Abl kinase inhibitor with antitumor activity for the study of chronic myelogenous leukemia (CML) and breast cancer. |
別名 | NRC-AN-019, NRC-019 |
分子量 | 517.43 |
分子式 | C25H17F6N5O |
CAS No. | 879507-25-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
AN-019 879507-25-2 Angiogenesis Cytoskeletal Signaling Tyrosine Kinase/Adaptors Bcr-Abl NRC019 NRC-AN019 AN 019 NRC 019 NRC-AN-019 AN019 NRC-019 NRC-AN 019 NRC Inhibitor inhibitor inhibit